Starwatch: Mars and Regulus will make for an eye-catching pair

Look into the western sky this week to see an eye-catching conjunction between Mars and Regulus, the brightest star in the constellation of Leo, the lion. The chart shows the view from London at 2300 BST on 16 June 2025.
The pair of celestial objects will be separated by less than a degree, less than twice the apparent diameter of the full moon. This means that as well as being an easy spot with the naked eye, they are close enough to fit into the same field of view when viewed through binoculars. Although they will move further apart as the week continues.
The colour difference between them will be striking. Mars will be red whereas Regulus shines with a blue-white colour. Regulus is the 21st brightest star in the night sky and lies about 79 light years away from us. It contains just over four times the mass of the sun, and has a diameter just over four times larger, too, giving out about 340 times the sun's energy.
From the southern hemisphere, too, the conjunction appears in the north-north-west. In addition, on 19 June, the moon will be close to Saturn in the constellation Pisces, the fishes.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Daily Mail​

28 minutes ago

• Daily Mail​

Erectile dysfunction drug Viagra has surprise new health benefit, scientists find - offering new hope to 3million ageing Britons

A surprising new health benefit has emerged from the sex drug Viagra - which means three million ageing Britons can now also enjoy a harder skull. The little blue tablet was found to increase the production of vital bone cells, preventing back pain and fractures in old age. Sildenafil - also known as Viagra - can help human stem cells transform into osteoblasts which help the human skeleton regenerate as it is completely replaced roughly once every 10 years. As humans get older, they lose more bone than is built, increasing the risk of breaks or osteoporosis, which makes bones brittle and painful. Follow-up tests on mice by Peking University also suggested a prevention of bone loss. Dr Menglong Hu and Dr Likun Wu told MailOnline: 'Our findings offer new insights into the physiological effects of the medicine. 'Sildenafil enhanced stem cell osteogenic differentiation and inhibited bone loss — it may usefully treat osteoporosis.' Viagra was invented as a heart drug in the 1980s before being found to help with erectile dysfunction. Some studies suggest it may also help reduce the risk of dementia. However, the have been cautions over the years that the drug could have some negative side effects, in particular if taken too much. A large quantity of the drug could result in a painful, 'uncomfortably and disproportionately large erection' called a priapism which could go on for hours. Some experts also found regularly taking the common drug may raise the risk of three serious eye conditions. Common side effects may include headaches, hot flushes, nausea, indigestion, dizziness and a stuffy nose. Nearly half of men between the ages of 40 and 70 suffer from erectile dysfunction in the UK - this is more than 4.5 million people. Though, reports suggest Viagra is now even becoming increasingly popular with younger individuals in their 20s and 30s. Last year, it emerged Viagra may help prevent dementia by boosting blood flow in the brain. 'This is the first trial to show that sildenafil gets into the blood vessels in the brain in people with this condition, improving blood flow and how responsive these blood vessels are,'Dr Alastair Webb, a neurologist and study author at Oxford University said.

The Independent

2 hours ago

• The Independent

Nearly 600 heat-related deaths expected in UK heatwave, researchers estimate

Nearly 600 people in England and Wales are predicted to die as a result of this week's heatwave, researchers have found. Experts at the London School of Hygiene and Tropical Medicine (LSHTM) and Imperial College London used decades of UK data to predict excess mortality during the hot temperatures from Thursday to Sunday. Their study, released on Saturday, forecasts that around 570 people will die because of the heat over the four days. The excess deaths are estimated to peak at 266 on Saturday when the heat will be at its most intense. London is predicted to have the greatest number of excess deaths with 129. The researchers said their assessment highlights how extreme heat poses a growing threat to public health in the UK. It follows a World Weather Attribution (WWA) research group study published on Friday which found the heatwave has been made about 100 times more likely and 2-4C hotter due to climate change. Dr Garyfallos Konstantinoudis, lecturer at the Grantham Institute at Imperial College London, said: 'Heatwaves are silent killers – people who lose their lives in them typically have pre-existing health conditions and rarely have heat listed as a contributing cause of death. 'This real-time analysis reveals the hidden toll of heatwaves and we want it to help raise the alarm. 'Heatwaves are an underappreciated threat in the UK and they're becoming more dangerous with climate change.' Dr Konstantinoudis warned that people should follow heat-health advice this weekend and check on older people, particularly those living alone. Temperatures had been forecast to hit 32C across the South East on Saturday and had already reached that level on Thursday in London. The UK Health Security Agency issued an amber heat-health alert covering all of England to warn vulnerable populations of the health risks, including 'a rise in deaths'. Dozens of people required treatment for heat-related illness at Royal Ascot on Thursday. The researchers used findings from published research on the relationship between heat and the number of daily deaths, regardless of the cause, in 34,753 areas of England and Wales. They combined these with high-resolution weather forecasts from the Copernicus climate change service to estimate how many heat-related deaths will occur. They estimated that 114 excess deaths would have occurred on Thursday, 152 on Friday, 266 on Saturday and 37 deaths on Sunday, when temperatures will fall to the mid-20s. People above 65 are expected to be hardest hit, with 488 of the estimated excess deaths, the report said. But the experts also warn that heat can be life-threatening for all ages, with 82 deaths estimated for people aged under 65. They also note that the analysis does not account for the effect of the heatwave occurring early in summer before people are acclimatised to hot temperatures, meaning deaths could be underestimated. A recent report by the UK Climate Change Committee estimated that heat-related deaths could rise to more than 10,000 in an average year by 2050 if fossil fuel burning causes warming to reach 2C. UN scientists warned this week that the world is in 'crunch time' to limit warming and has three years left to prevent global average temperature rises exceeding 1.5C. Professor Antonio Gasparrini, of the LSHTM, said: 'Increases of just a degree or two can be the difference between life and death. 'Every fraction of a degree of warming will cause more hospital admissions and heat deaths, putting more strain on the NHS.' Dr Malcolm Mistry, assistant professor at the LSHTM, said: 'Exposure to temperatures in the high 20s or low 30s may not seem dangerous, but they can be fatal, particularly for people aged over 65, infants, pregnant people and those with pre-existing health conditions. 'Unless effective mitigation and adaptive measures are put in place in the coming years, the risk of large heat-related death events is set to increase in the UK – we have a large ageing population and warming is expected to increase to 2C by 2050 and as high as 3C this century.' Dr Lorna Powell, an NHS urgent care doctor in east London who was not involved in the study, said: 'We are seeing cases of heat-related illnesses rising in our urgent care departments. 'Heat exhaustion can quickly trigger more serious illnesses as dehydration sets in and the cardiovascular system becomes overwhelmed.'

The Independent

2 hours ago

• The Independent

Weight loss jab could be used to treat migraines

Weight loss jabs could cut the number of migraines sufferers experience by half, research suggests. The drugs, similar to Ozempic and Wegovy, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. Researchers have discovered, GLP-1 drug liraglutide, commonly used to treat diabetes, has the potential to significantly reduce migraine frequency. Migraines affect approximately 6 million people in the UK, according to the NHS. Attacks can last for three days causing pain, nausea, vomiting, dizziness and sensitivity to light, sound and smells. Researchers at the Headache Centre of the University of Naples gave 26 adults with obesity and chronic migraines the drug liraglutide. The study presented at the European Academy of Neurology (EAN) Congress 2025, found those who had the drug reported an average of 11 fewer headache days per month. Participants also experienced meaningful improvements in quality of life, work, study, and social functioning within just two weeks of taking the drug. 'Most patients felt better within the first two weeks and reported quality of life improved significantly', said lead researcher Dr Simone Braca. 'The benefit lasted for the full three-month observation period, even though weight loss was modest and statistically non-significant.' Growing evidence has linked subtle increases in intracranial pressure to migraine attacks. It's caused by a rise in the pressure of cerebrospinal fluid – which surrounds the brain and spinal cord. This increase in pressure can happen because of a severe head injury, stroke, a brain tumour or high blood pressure. But GLP-1-receptor agonists such as liraglutide reduce cerebrospinal fluid secretion and have already proved effective in treating idiopathic intracranial hypertension (IIH). Patients in the study were screened to exclude papilledema (optic disc swelling resulting from increased intracranial pressure) and sixth nerve palsy, ruling out IIH. Dr Braca and colleagues believe GLP-1 drugs may reduce the release of CGRP (calcitonin gene-related peptide), a key molecule behind migraines. 'We think that, by modulating cerebrospinal fluid pressure and reducing intracranial venous sinuses compression, these drugs produce a decrease in the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide', Dr Braca said. 'That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway.' Given liraglutide's established use in type 2 diabetes and obesity, it may represent a promising case of drug repurposing in neurology, study authors said.